Your browser doesn't support javascript.
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.
Hoffmann, Markus; Schroeder, Simon; Kleine-Weber, Hannah; Müller, Marcel A; Drosten, Christian; Pöhlmann, Stefan.
  • Hoffmann M; Deutsches Primatenzentrum-Leibniz Institute for Primate Research, Göttingen, Germany.
  • Schroeder S; Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany.
  • Kleine-Weber H; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany.
  • Müller MA; German Centre for Infection Research, associated partner Charité, Berlin, Germany.
  • Drosten C; Deutsches Primatenzentrum-Leibniz Institute for Primate Research, Göttingen, Germany.
  • Pöhlmann S; Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany.
Antimicrob Agents Chemother ; 64(6)2020 05 21.
Article in English | MEDLINE | ID: covidwho-1723509
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe acute respiratory syndrome-related coronavirus Language: English Year: 2020 Document Type: Article Affiliation country: AAC.00754-20

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe acute respiratory syndrome-related coronavirus Language: English Year: 2020 Document Type: Article Affiliation country: AAC.00754-20